UNIVEST FINANCIAL Corp Lowers Stock Holdings in Thermo Fisher Scientific Inc. $TMO

UNIVEST FINANCIAL Corp cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 34,403 shares of the medical research company’s stock after selling 1,112 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.1% of UNIVEST FINANCIAL Corp’s holdings, making the stock its 20th biggest holding. UNIVEST FINANCIAL Corp’s holdings in Thermo Fisher Scientific were worth $19,935,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. Advisor OS LLC grew its stake in Thermo Fisher Scientific by 14.2% in the fourth quarter. Advisor OS LLC now owns 999 shares of the medical research company’s stock worth $579,000 after purchasing an additional 124 shares in the last quarter. Dogwood Wealth Management LLC raised its position in Thermo Fisher Scientific by 93.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 83 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 40 shares in the last quarter. Marco Investment Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. Marco Investment Management LLC now owns 10,846 shares of the medical research company’s stock worth $6,285,000 after buying an additional 70 shares during the period. BankPlus Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $220,000. Finally, Midwest Trust Co increased its stake in shares of Thermo Fisher Scientific by 1.0% during the fourth quarter. Midwest Trust Co now owns 90,066 shares of the medical research company’s stock valued at $52,189,000 after buying an additional 868 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $464.64 on Friday. The firm has a 50-day simple moving average of $493.53 and a two-hundred day simple moving average of $546.70. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The firm has a market cap of $172.67 billion, a price-to-earnings ratio of 25.54, a PEG ratio of 2.06 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were issued a dividend of $0.47 per share. The ex-dividend date was Friday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 5,800 shares of company stock valued at $2,963,544 in the last three months. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on TMO shares. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday. Barclays reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Citigroup lifted their price objective on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a report on Friday, January 30th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $619.65.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Erste Group raised its FY2027 earnings estimate for Thermo Fisher, signaling slightly better long-term profit expectations for the company. Article
• Positive Sentiment: Thermo Fisher was included in CNBC’s “Final Trades,” which can reinforce investor interest and visibility in the stock. Article
• Neutral Sentiment: Thermo Fisher continues to be viewed as a key player in life sciences tools, and a new market note questioned whether the recent pullback makes the shares more attractive from a valuation standpoint. Article
• Neutral Sentiment: Proscia’s MedTech Breakthrough Award win mentioned Thermo Fisher among industry peers, but the item was focused on Proscia rather than a direct company-specific catalyst for TMO. Article
• Negative Sentiment: Wells Fargo cut its price target on Thermo Fisher from $675 to $615, which can weigh on sentiment even though the firm kept an overweight rating. Article

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.